ImmunityBio, Inc. Common Stock (IBRX) is a publicly traded Healthcare sector company. As of July 6, 2026, IBRX trades at $9.49 with a market cap of $9.89B and a P/E ratio of -11.11. IBRX moved +0.00% today. Year to date, IBRX is +376.77%; over the trailing twelve months it is +257.58%. Its 52-week range spans $1.83 to $12.43. Analyst consensus is strong buy with an average price target of $13.00. Rallies surfaces IBRX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Rallies tracks IBRX insider trades, Form 4 activity, executive purchases, executive sales, shares, prices, and transaction dates when available.
| Metric | Value |
|---|---|
| Price | $9.49 |
| Market Cap | $9.89B |
| P/E Ratio | -11.11 |
| EPS | $-0.85 |
| Dividend Yield | 0.00% |
| 52-Week High | $12.43 |
| 52-Week Low | $1.83 |
| Volume | 8.18K |
| Avg Volume | 0 |
| Revenue (TTM) | $140.98M |
| Net Income | $-854.60M |
| Gross Margin | 99.34% |
3 analysts cover IBRX: 0 strong buy, 3 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $13.00.